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A

22-day-old male neonate was referred
to our emergency department from a
community hospital after realization
that an acute acetaminophen overdose had
occurred, following routine circumcision.
The patient had been born at 40 weeks’ gestation after an uneventful delivery to a gravida 1
mother. The pregnancy had been complicated by
pregnancy-induced hypertension, treated with
labetalol. Prior to the overdose, the baby had
been well.
On the day of presentation, the patient had
been given about 800 mg (200 mg/kg) of acetaminophen by his parents before circumcision.
The parents had been instructed, by their physician, to give him 40 mg of acetaminophen before
bringing him to the hospital for the procedure.
The patient’s weight was 4.1 kg; thus, this was
an intended dose of 10 mg/kg. The bottle of
acetaminophen showed a concentration of 80
mg/mL, which was misinterpreted by the parents, in that they believed that the bottle contained 80 mg of acetaminophen in total. The
child was given 10 mL, or about half of the bottle, with the intent of giving him 40 mg. The
child underwent his circumcision, and, following
the procedure, the physician instructed the parents to give him another dose of acetaminophen
if he seemed uncomfortable. At that point, the
mother commented that “it seemed like a lot of
medicine,” and the error was discovered.
The acetaminophen blood concentration
drawn four hours after the overdose was substan-

Key points
•

Acetaminophen overdose is a leading cause of acute liver failure in
adults and a major cause of acute liver failure in children.

•

Developmental differences in hepatic metabolism exist that influence
the risk of hepatotoxicity following acetaminophen overdose among
infants compared with adults.

•

Infants and children are particularly susceptible to acute
acetaminophen overdose because of dosing errors.

•

Strategies to prevent potentially fatal overdoses need to target both
patient-based and systems-based interventions.
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tially elevated at 1243 (upper end of therapeutic
range 66–199) µmol/L. Initial liver indices were
normal. Total bilirubin level was 20.4 (normal 3–
17) µmol/L, glucose level was 5.7 (normal 4–8)
mmol/L and albumin level was 33 (normal 32–
45) g/L. Complete blood count, electrolytes and
renal function tests were normal. Blood gas,
international normalized ratio and partial thromboplastin time tests were not conducted.
The regional poison control centre was consulted. Given that the patient had received more
than the toxic dose of 150 mg/kg and because
the four-hour blood concentration level of acetaminophen was in the probable toxicity range on
the Rumack–Matthew nomogram, treatment
with N-acetylcysteine was recommended. Activated charcoal was not given.
Treatment was started within eight hours of the
overdose. A standard intravenous N-acetylcysteine protocol was started with 150 mg/kg of Nacetylcysteine mixed in 12 mL of 5% dextrose (3
mL/kg) and infused over 60 minutes, followed by
50 mg/kg of N-acetylcysteine mixed in 40 mL of
5% dextrose (10 mL/kg) and infused over 4 hours,
then 100 mg/kg of N-acetylcysteine in 80 mL of
5% dextrose (20 mL/kg) infused over 16 hours.
The patient was monitored on the general pediatrics floor and continued to breastfeed well.
Liver indices were repeated 25 hours after the
ingestion (18 h after the infusion of N-acetylcysteine had started) and remained normal. At that
point, no acetaminophen was detectable in the
patient’s blood serum. The N-acetylcysteine infusion was stopped after completion of the 21-hour
protocol. The patient was discharged home after
48 hours, to follow up with his community physician. The patient remained clinically well and did
not show evidence of long-term consequences of
the accidental overdose.

Discussion
Acetaminophen is a commonly used antipyretic
and analgesic in children that can have severe
consequences when overdose occurs. Aceta-
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minophen overdose is a major cause of acute
liver failure and is the most common identifiable
cause of acute liver failure in children.1 Repeated
supratherapeutic dosing, accidental overdose due
to error and intentional ingestion can all result in
acute liver failure and even death.
Hepatic toxicity
The toxicity of acetaminophen overdose has long
been recognized.2 Potentially toxic doses are
those that are greater than 150 mg/kg/dose in
children and greater than 7–10 g/dose in adults.
With the advent of many combination analgesic
medications, the potential for unintentional overdose has increased.3 In the United States, two
concentrations of liquid formulations of acetaminophen for infants are now available, further
increasing the risk of incorrect dosing.4
Acetaminophen hepatotoxicity is caused by
the formation of a toxic metabolite, N-acetyl-pbenzoquinoneimine (NAPQI). When acetaminophen is used in therapeutic doses, most of
the drug is metabolized via glucuronidation and
sulfation; a very small amount of acetaminophen
is metabolized to NAPQI by the hepatic enzyme
cytochrome P450 2E1 (CYP2E1).5 N-acetyl-pbenzoquinoneimine is then conjugated by glutathione to form the benign metabolite, mercapturic acid, which is excreted in the urine. The
potential for hepatotoxicity develops when large
doses of acetaminophen saturate the typical conjugation pathways and overwhelm available glutathione stores, leading to reduced clearance of
the toxic metabolite. Accumulation of the toxic
metabolite can then exert untoward effects on
key cellular structures and functions (Figure 1).
Developmental differences in drug
metabolism
Hepatic drug metabolism is classically thought
to occur via two distinct routes: phase I and
phase II metabolism.6 Phase I reactions are frequently mediated by cytochrome P450 enzymes,
such as CYP2E1 in the case of acetaminophen.
Phase II reactions involve conjugation pathways
such as glucuronidation, sulfation and glutathione conjugation.
Both phases are important in acetaminophen
metabolism, with their relative importance varying with age. In neonates and infants, rates of
glucuronidation are less than in adults, with a
compensatory increase in rates of sulfation.6
There are considerable differences in the maturation of CYP enzyme function depending on the
isoenzyme species of interest. For example,
NAPQI, the toxic metabolite, is primarily the
product of CYP2E1 metabolism, and there is
evidence that younger children have a relative

immaturity in CYP2E1 metabolism, which
would substantially reduce the production of this
toxic metabolite in infants.7 After birth, CYP2E1
protein expression and activity increases, reaching adult levels by about 1 year of age.7
The ability of the liver to metabolize acetaminophen changes with age owing to differences
in activity of these key metabolic pathways.
Although the mechanism of acetaminophen toxicity is well recognized, the clinical implications of
age-related differences and the ontogeny of hepatic
pathways may not be commonly appreciated.
Treatment options and controversies
Hepatotoxicity related to an acute acetaminophen overdose generally has a good prognosis, particularly with appropriate treatment.
When treatment is started within 8 hours of an
acute ingestion, hepatotoxicity is as low as 10%.8
Based on observational data from the Pediatric
Acute Liver Failure study group, recovery
occurred in 94% of instances of acetaminophen
overdose in children when treated appropriately.1
Treatment options include trying to limit the
absorption of acetaminophen and reducing the
accumulation of the toxic metabolite, NAPQI.
Activated charcoal can be used to try to reduce
the absorption of acetaminophen if the patient
presents within one hour of the ingestion.9 Otherwise, the treatment of choice is use of a specific
antidote, N-acetylcysteine, which reduces the
hepatotoxic effects of acetaminophen overdose
by replenishing glutathione stores, thereby
enhancing production of the nontoxic metabolites. Ideally, treatment with N-acetylcysteine
should be started within 8–10 hours of an acute
ingestion. However, beneficial effects can be
appreciated even if therapy is started up to 24
hours after the ingestion.9
N-acetylcysteine can be given orally or by
intravenous infusion, and controversy exists
about the preferred route of administration.
There are no randomized controlled trials that
compare the 2 modes of therapy; both are
deemed effective.8 In Canada, intravenous Nacetylcysteine therapy is essentially the only
route used, whereas in the US, both intravenous
and oral therapy are available. Intravenous Nacetylcysteine has only recently become available in the US.
Intravenous N-acetylcysteine is associated with
fewer of the adverse effects seen with the oral
preparation, such as nausea, vomiting, abdominal
pain, diarrhea and rash, but it carries a higher risk
of anaphylactoid reactions.9 When patients present
relatively late after ingestion, oral N-acetylcysteine protocols provide a higher dose given over a
longer period, which may be an advantage. 2,10
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Prevention of overdose and medication
errors in children
This report highlights the issue of accurate dosing in pediatrics. In this situation, well-educated
parents miscalculated the dose of acetaminophen
for their newborn. Correct dosing in pediatrics is
challenged by weight-based dosing and the conversion of a weight-based dose to a volume (i.e.,

However, the gastrointestinal adverse effects associated with oral therapy are a substantial disadvantage, notably if this results in a longer time for
drug absorption and hence a longer time to reach
therapeutic effect.2 Since the introduction and
adoption of routine use of N-acetylcysteine therapy, the mortality rate in acetaminophen overdose
has declined from 3% to 0.7%.11
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Figure 1: Acetaminophen metabolism. N-acetyl-p-aminophenol (APAP) is the active component of acetaminophen and is metabolized by 3 pathways: glucuronidation, sulfation and glutathione conjugation. Glucuronidation and sulfation produce nontoxic metabolites for excretion. N-acetyl-p-benzoquinoneimine
(NAPQI) is a toxic intermediate produced by cytochrome P450 2E1 (CYP2E1; the main metabolizing agent)
and cytochrome P450 3A4 (CYP3A4) metabolism. NAPQI is then conjugated by glutathione to form a nontoxic metabolite for excretion.
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milligrams to millilitres), as many children rely
on liquid preparations.
Medication error is a serious problem in the
care of children.12 Based on a report from US
poison control centres and the American Academy of Pediatrics, 11% of children under the age
of 6 years who are exposed to pharmaceuticals
experience a medication error (incorrect medication, incorrect dose or incorrect route of administration).13 This report analyzed 238 instances of
serious medication error in children under six
years of age reported to poison control centres
across the US between 2000 and 2004. Incorrect
dosing topped the list of errors and was more
common among children less than 1 year of age
or when less than 1 mL of the medication was to
be given. Of the 238 instances, 162 occurred in
the home. Acetaminophen overdose was the
most common single agent responsible for a serious medication error (e.g., life-threatening,
resulting in substantial morbidity or mortality).
There were a total of 24 deaths reported and, of
these, one-third were due to acetaminophen
overdose. Comparable Canadian data have not
yet been compiled.
Errors associated with medication administration represent an important opportunity for preventive health care, as these are avoidable events.
There is a large body of literature on the prevention of medication errors within health care institutions, but there is a paucity of evidence to
guide us in how to reduce medication errors in
the outpatient setting.
Intuitively, strategies that improve parent
education and promote parent–physician communication should be effective. However,
research has not yet identified any single solution. In one study, parent–physician communication on its own did not seem to help.14 Lemer
and colleagues did not find a correlation
between reduced error rates and provision of
advice by a health care provider. 14 Variables
that were associated with higher error rates
were children less than five years of age and
children taking two or more medications. A
major limitation of this study was that it relied
on parent recall to assess whether advice was
given.14 The use of parent recall in research has
the advantage of being realistic by assessing
whether the parents perceived that they were
given advice, but the findings more likely
speak to the need for better ways to provide
education to parents. In this study, most advice
was given by verbal communication with very
little written communication. 14 The effectiveness of written information, including personalized dosages and diagrams, is an area to be
explored.

Potential for systems prevention
and improved safety
Although physicians and pharmacists should
continue to educate parents and caregivers
regarding the medications prescribed, one-to-one
communication cannot be the sole approach to
reducing errors in medication administration.
Error reduction on a large scale requires systems-based interventions and prevention.
Hepatic toxicity related to acetaminophen has
received increasing attention from regulatory
agencies. Both the US Food and Drug Administration and Health Canada have issued advisories
to increase public awareness of the potential for
hepatotoxicity with use of acetaminophen. There
is a heightened awareness of medication safety
in pediatrics, and new efforts are being put
toward reducing adverse events. Regulations
banning cough and cold medications for use in
children under the age of 6 years is one such
example. In 2009, Health Canada revised the
labelling standards for acetaminophen-containing products to enforce stronger warnings on
packaging about the risk of overdose.15 Revisions
also mandate the inclusion of weight-based dosing charts with each product.15
Although regulatory bodies have begun taking
steps to improve labelling and raise awareness of
potential harm, there remains substantial room
for practical and point-of-care interventions.
In an expert panel review of deaths caused by
cough and cold medications, supratherapeutic
doses were identified in most of the fatal cases.16
One factor that was thought to contribute to overdoses was the lack of an appropriate device to
administer the medication.16,17 Spoons are often
used by parents, but are inaccurate,17 as are liquid
droppers. From a systems-based perspective,
improving packaging to facilitate calculation and
delivery of an appropriate dose may be a practical
intervention.17 It may also be useful to have children’s acetaminophen behind the counter so that
parents are counselled by a pharmacist before
purchasing the medication. This counselling
could include the provision of written information specifying the child’s weight (based on the
parent’s report), dose and volume to be given.
Conclusion
Acetaminophen is a commonly used medication
that can have serious adverse effects in the context
of overdose. Although a specific antidote, Nacetylcysteine, is available and effective, controversy exists about the best route of administration.
The widespread use and availability of acetaminophen make the potential for overdose a
population health concern and warrants a systems-based approach to preventing adverse out-
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comes. Although some efforts have been made
to raise awareness of hepatotoxicity related to
acetaminophen use, concern with acetaminophen’s availability as an over-the-counter
medication remains.
Fortunately, our patient had a positive outcome and did not have adverse effects of the
overdose of acetaminophen. It is important to
note that there are developmental differences in
hepatic metabolism that may affect the hepatotoxicity seen in infants and young children. The
clinical implications of these differences warrant
further investigation.
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